Literature DB >> 34850156

Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?

Agata M Kieliszek1,2, Nikoo Aghaei1,2, Blessing I Bassey-Archibong1,3, Sheila K Singh1,2,3.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 34850156      PMCID： PMC8804891          DOI： 10.1093/neuonc/noab267

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.

Authors:  Franziska Maria Ippen; Julia Katharina Grosch; Megha Subramanian; Benjamin Macfarlane Kuter; Bianca M Liederer; Emile G Plise; Joana Liliana Mora; Naema Nayyar; Stephen Paul Schmidt; Anita Giobbie-Hurder; Maria Martinez-Lage; Scott L Carter; Daniel P Cahill; Hiroaki Wakimoto; Priscilla Kaliopi Brastianos
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

2.  Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.

Authors:  Alexandra S Zimmer; Seth M Steinberg; Dee Dee Smart; Mark R Gilbert; Terri S Armstrong; Eric Burton; Nicole Houston; Nadia Biassou; Brunilde Gril; Priscilla K Brastianos; Scott Carter; David Lyden; Stanley Lipkowitz; Patricia S Steeg
Journal:  Future Oncol       Date:  2020-04-09       Impact factor: 3.404

3.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

4.  An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.

Authors:  Teresa Amaral; Heike Niessner; Tobias Sinnberg; Ioannis Thomas; Andreas Meiwes; Claus Garbe; Marlene Garzarolli; Ricarda Rauschenberg; Thomas Eigentler; Friedegund Meier
Journal:  Neurooncol Adv       Date:  2020-10-22

5.  Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.

Authors:  Guo Chen; Nitin Chakravarti; Kimberly Aardalen; Alexander J Lazar; Michael T Tetzlaff; Bradley Wubbenhorst; Sang-Bae Kim; Scott Kopetz; Alicia A Ledoux; Y N Vashisht Gopal; Cristiano Goncalves Pereira; Wanleng Deng; Ju-Seog Lee; Katherine L Nathanson; Kenneth D Aldape; Victor G Prieto; Darrin Stuart; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

6.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Authors:  Priscilla K Brastianos; Scott L Carter; Gad Getz; William C Hahn; Sandro Santagata; Daniel P Cahill; Amaro Taylor-Weiner; Robert T Jones; Eliezer M Van Allen; Michael S Lawrence; Peleg M Horowitz; Kristian Cibulskis; Keith L Ligon; Josep Tabernero; Joan Seoane; Elena Martinez-Saez; William T Curry; Ian F Dunn; Sun Ha Paek; Sung-Hye Park; Aaron McKenna; Aaron Chevalier; Mara Rosenberg; Frederick G Barker; Corey M Gill; Paul Van Hummelen; Aaron R Thorner; Bruce E Johnson; Mai P Hoang; Toni K Choueiri; Sabina Signoretti; Carrie Sougnez; Michael S Rabin; Nancy U Lin; Eric P Winer; Anat Stemmer-Rachamimov; Matthew Meyerson; Levi Garraway; Stacey Gabriel; Eric S Lander; Rameen Beroukhim; Tracy T Batchelor; Jose Baselga; David N Louis
Journal:  Cancer Discov       Date:  2015-09-26       Impact factor: 39.397

Review 7.  Brain metastasis-initiating cells: survival of the fittest.

Authors:  Mohini Singh; Branavan Manoranjan; Sujeivan Mahendram; Nicole McFarlane; Chitra Venugopal; Sheila K Singh
Journal:  Int J Mol Sci       Date:  2014-05-22       Impact factor: 5.923

8.  The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.

Authors:  Cedric Tehranian; Laura Fankhauser; Patrick N Harter; Colin D H Ratcliffe; Pia S Zeiner; Julia M Messmer; Dirk C Hoffmann; Katharina Frey; Dana Westphal; Michael W Ronellenfitsch; Erik Sahai; Wolfgang Wick; Matthia A Karreman; Frank Winkler
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 12.300

Review 9.  Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.

Authors:  Catherine H Han; Priscilla K Brastianos
Journal:  Front Oncol       Date:  2017-09-25       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.